Furthermore, CANTOS and TRACK trials have evaluated the role of IL-1 inhibition in the treatment of several inflammatory disorders, such as coronary artery disease, T2DM and rheumatoid arthritis (Qamar & Rader, 2012; Ruscitti et al., 2019). Here, IL1B is linked to type 2 diabetes mellitus.